“Fabry Disease Therapies such as GALAFOLD, ELFABRIO (PRX-102), 4D-310, ST-920, Venglustat, and others”
The Fabry Disease market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Fabry Disease therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Fabry Disease Market Insight, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Fabry Disease Market by downloading the comprehensive report from DelveInsight @ Fabry Disease Therapeutics Market
Key Takeaways from Fabry Disease Market Report
-
The Growth of the Fabry Disease Market is expected to be primarily driven by an expanding patient population, and advancement in diagnostic methods.
-
The leading Fabry Disease Companies such as Genzyme, Shire, Takeda, Protalix Biotherapeutics, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, and others
-
Promising Fabry Disease Therapies such as GALAFOLD, ELFABRIO (PRX-102), 4D-310, ST-920, Venglustat, and others.
-
The total diagnosed prevalent cases of Fabry Disease in the 7MM in 2022 were 15,290, out of which the highest cases were observed in the United States. EU4 countries and the UK accounted for 5,245 cases, whereas Japan had 1,690 cases in 2022.
-
In the US, in 2022, 4,345 males and 4,011 females were affected with Fabry disease. These numbers are estimated to increase by 2034.
-
As per DelveInsight’s assessments, Fabry Disease is more prevalent in males than females in the United States.
-
August 2024:- Sanofi- This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide guidance on how the infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
-
August 2024:- UniQure Biopharma B.V.- This is an open-label, multi-center study to evaluate safety, tolerability, and exploratory efficacy of a single dose of intravenously-administered AMT-191. The plan is to investigate 2 sequential dose cohorts with 3-6 Participants per cohort. Participants will continue receiving regularly scheduled enzyme replacement therapy (ERT) until they meet the criteria for withdrawal.
Gain a competitive edge in the Fabry Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Fabry Disease Treatment Drugs
Fabry Disease Treatment Market
Fabry disease treatment consists of enzyme replacement therapy (ERT), oral chaperone therapy, and adjunctive treatments, including ACE inhibitors or angiotensin receptor blockers, antiplatelet drugs, and analgesics. Studies have shown that ERT can delay, but not always prevent, some of the clinical complications of FD. The effective management of Fabry disease requires a multidisciplinary approach with comprehensive therapy of intravenously administered ERT or chaperone therapy and adjunct therapies, including lifestyle modifications and prophylactic medications.
Fabry Disease Emerging Drugs Profile
-
Venglustat: Sanofi Genzyme
Discover key developments and opportunities in the Fabry Disease Market. Click here to learn more from DelveInsight’s latest report @ Fabry Disease Market Size
Fabry Disease Drugs and Companies
-
GALAFOLD: Amicus Therapeutics
-
ELFABRIO (PRX-102): Chiesi Global Rare Diseases/Protalix Biotherapeutics
-
4D-310: 4D Molecular Therapeutics
-
ST-920: Sangamo Therapeutics
-
Venglustat: Sanofi Genzyme
Fabry Disease Market Dynamics
Fabry Disease market dynamics are influenced by epidemiological trends, advancements in diagnostics, therapeutic developments, and the regulatory environment. Continued research and innovation are essential to meet the growing demand for effective treatments and improve the quality of life for patients affected by this condition.
Download DelveInsight’s Fabry Disease Market report today and stay ahead in this rapidly evolving field. @ Fabry Disease Clinical Trials
Scope of the Fabry Disease Market Report
-
Coverage- 7MM
-
Fabry Disease Companies- Genzyme, Shire, Takeda, Protalix Biotherapeutics, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, and others
-
Fabry Disease Therapies- GALAFOLD, ELFABRIO (PRX-102), 4D-310, ST-920, Venglustat, and others.
-
Fabry Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
-
Fabry Disease Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement
Download the report to understand which factors are driving Fabry Disease market trends @ Fabry Disease Market Trends
Table of Content
1. Key Insights
2. Fabry Disease Market Report Introduction
3. Fabry Disease Market Overview At A Glance
4. Fabry Disease Epidemiology And Market Forecast Methodology
5. Key Events
6. Executive Summary Of Fabry Disease
7. Fabry Disease Market Disease Background And Overview
8. Fabry Disease Epidemiology And Patient Population
9. Fabry Disease Patient Journey
10. Fabry Disease Marketed Drugs
11. Fabry Disease Emerging Drugs
12. Fabry Disease: Seven Major Market Analysis
13. Key Opinion Leaders’ Views
14. Fabry Disease Swot Analysis
15. Fabry Disease Unmet Needs
16. Fabry Disease Market Access And Reimbursement
17. Appendix
18. Delveinsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/